OBJECTIVE: Tight junction (TJ) proteins claudin-3 and claudin-4 may be differentially expressed in uterine serous papillary carcinoma (USPC), a rare form of endometrial cancer characterized by a particularly poor prognosis. Our aim was to determine the expression pattern and prognostic relevance of claudin-3 and claudin-4 in a large cohort of endometrial cancer patients of diverse histological type and stage. METHODS: Claudin-3 and claudin-4 expression was studied in a cohort of 287 patients with endometrial cancer including 137 cases of USPC or clear-cell histology using immunohistochemistry. Patients were completely surgically staged. Outcome data is available on all 287 patients. RESULTS: The rate of claudin-3 and claudin-4 expression was significantly higher in USPC and clear-cell endometrial cancer compared to endometrioid endometrial cancer (claudin-3: 78% and 61% versus 38%, p<.0001; claudin-4: 56% and 44% versus 9%, p<.0001). Furthermore, expression of both TJ proteins was significantly associated with poor clinical outcome (claudin-3, DFS RR 1.70, p=.0087, OS RR 1.62, p=.0247; claudin-4, DFS RR 2.66, p<0.0001, and OS RR 2.50, p<0.0001). However, both markers did not maintain prognostic independence in multivariate analyses, as their expression was tightly associated with more advanced disease stages (p<.0001 for both), and higher nuclear grade (p<.0001 for both). CONCLUSION: These clinical observations confirm the hypothesis based on preclinical evidence that increased expression of claudin-3 and claudin-4 may contribute to the aggressive phenotype of endometrial cancer of serous papillary or clear-cell histology and suggest their potential utility as diagnostic biomarkers and possible targets for therapeutic intervention.
OBJECTIVE: Tight junction (TJ) proteins claudin-3 and claudin-4 may be differentially expressed in uterine serous papillary carcinoma (USPC), a rare form of endometrial cancer characterized by a particularly poor prognosis. Our aim was to determine the expression pattern and prognostic relevance of claudin-3 and claudin-4 in a large cohort of endometrial cancerpatients of diverse histological type and stage. METHODS:Claudin-3 and claudin-4 expression was studied in a cohort of 287 patients with endometrial cancer including 137 cases of USPC or clear-cell histology using immunohistochemistry. Patients were completely surgically staged. Outcome data is available on all 287 patients. RESULTS: The rate of claudin-3 and claudin-4 expression was significantly higher in USPC and clear-cell endometrial cancer compared to endometrioid endometrial cancer (claudin-3: 78% and 61% versus 38%, p<.0001; claudin-4: 56% and 44% versus 9%, p<.0001). Furthermore, expression of both TJ proteins was significantly associated with poor clinical outcome (claudin-3, DFS RR 1.70, p=.0087, OS RR 1.62, p=.0247; claudin-4, DFS RR 2.66, p<0.0001, and OS RR 2.50, p<0.0001). However, both markers did not maintain prognostic independence in multivariate analyses, as their expression was tightly associated with more advanced disease stages (p<.0001 for both), and higher nuclear grade (p<.0001 for both). CONCLUSION: These clinical observations confirm the hypothesis based on preclinical evidence that increased expression of claudin-3 and claudin-4 may contribute to the aggressive phenotype of endometrial cancer of serous papillary or clear-cell histology and suggest their potential utility as diagnostic biomarkers and possible targets for therapeutic intervention.
Authors: Patrick Michl; Claudia Barth; Malte Buchholz; Markus M Lerch; Monika Rolke; Karl-Heinz Holzmann; Andre Menke; Heiko Fensterer; Klaudia Giehl; Matthias Löhr; Gerhard Leder; Takeshi Iwamura; Guido Adler; Thomas M Gress Journal: Cancer Res Date: 2003-10-01 Impact factor: 12.701
Authors: Leticia B A Rangel; Rachana Agarwal; Theresa D'Souza; Ellen S Pizer; Piero L Alò; Wayne D Lancaster; Lucie Gregoire; Donald R Schwartz; Kathleen R Cho; Patrice J Morin Journal: Clin Cancer Res Date: 2003-07 Impact factor: 12.531
Authors: Anna-Mária Tokés; Janina Kulka; Sándor Paku; Agnes Szik; Csilla Páska; Pál Kaposi Novák; László Szilák; András Kiss; Krisztina Bögi; Zsuzsa Schaff Journal: Breast Cancer Res Date: 2005-01-31 Impact factor: 6.466
Authors: Maria C Todd; Heather M Petty; Jonathan M King; Brytanie N Piana Marshall; Rebecca A Sheller; Maria E Cuevas Journal: Oncol Lett Date: 2015-04-28 Impact factor: 2.967
Authors: Basile Tessier-Cloutier; Dawn R Cochrane; Anthony N Karnezis; Shane Colborne; Jamie Magrill; Aline Talhouk; Jonathan Zhang; Samuel Leung; Christopher S Hughes; Anna Piskorz; Angela S Cheng; Kendall Greening; Andreas du Bois; Jacobus Pfisterer; Robert A Soslow; Stefan Kommoss; James D Brenton; Gregg B Morin; C Blake Gilks; David G Huntsman; Friedrich Kommoss Journal: Hum Pathol Date: 2020-04-29 Impact factor: 3.466
Authors: Jianghong Li; Cheryl A Sherman-Baust; Miyun Tsai-Turton; Robert E Bristow; Richard B Roden; Patrice J Morin Journal: BMC Cancer Date: 2009-07-20 Impact factor: 4.430